PacBio Announces Appointment of Chris Smith to Board of Directors
PacBio (NASDAQ: PACB) announced the appointment of Chris Smith to its Board of Directors, effective immediately. Smith, currently CEO of NeoGenomics (NASDAQ:NEO), brings extensive experience in life sciences and healthcare industries. He previously served as Chairman and CEO of Ortho Clinical Diagnostics and CEO of Cochlear
The appointment aims to leverage Smith's expertise in diagnostics and laboratory testing markets as PacBio continues its expansion into clinical genomics. Concurrent with Smith's appointment, David Meline, who has served on the Board since 2023, is stepping down from his position.
Christian Henry, PacBio's President and CEO, highlighted Smith's deep expertise in clinical diagnostics and genomics, along with his experience in scaling high-growth companies, as valuable assets for PacBio's future growth in the clinical genomics market.
PacBio (NASDAQ: PACB) ha annunciato la nomina di Chris Smith nel suo Consiglio di Amministrazione, con effetto immediato. Smith, attualmente CEO di NeoGenomics (NASDAQ:NEO), porta un'ampia esperienza nei settori delle scienze della vita e della sanità. In precedenza ha ricoperto il ruolo di Presidente e CEO di Ortho Clinical Diagnostics e CEO di Cochlear.
La nomina mira a sfruttare l'esperienza di Smith nei mercati dei diagnostici e dei test di laboratorio mentre PacBio continua la sua espansione nella genomica clinica. Contestualmente alla nomina di Smith, David Meline, che fa parte del Consiglio dal 2023, si dimette dalla sua posizione.
Christian Henry, Presidente e CEO di PacBio, ha sottolineato l'ampia esperienza di Smith nei diagnostici clinici e nella genomica, insieme alla sua esperienza nella scalabilità di aziende in crescita, come risorse preziose per la futura crescita di PacBio nel mercato della genomica clinica.
PacBio (NASDAQ: PACB) anunció la nombramiento de Chris Smith en su Junta Directiva, con efectos inmediatos. Smith, actualmente CEO de NeoGenomics (NASDAQ:NEO), aporta una amplia experiencia en las ciencias de la vida y las industrias de la salud. Anteriormente, se desempeñó como Presidente y CEO de Ortho Clinical Diagnostics y CEO de Cochlear.
El nombramiento tiene como objetivo aprovechar la experiencia de Smith en los mercados de diagnóstico y pruebas de laboratorio mientras PacBio continúa su expansión en la genómica clínica. Concurrentemente con el nombramiento de Smith, David Meline, quien ha estado en la Junta desde 2023, está renunciando a su posición.
Christian Henry, Presidente y CEO de PacBio, destacó la profunda experiencia de Smith en diagnósticos clínicos y genómica, junto con su experiencia en escalar empresas en rápido crecimiento, como activos valiosos para el futuro crecimiento de PacBio en el mercado de la genómica clínica.
PacBio (NASDAQ: PACB)는 Chris Smith를 이사회의 임명으로 즉시 효과가 있음을 발표했습니다. 현재 NeoGenomics (NASDAQ:NEO)의 CEO인 Smith는 생명 과학 및 의료 산업에서 폭넓은 경험을 가지고 있습니다. 그는 이전에 Ortho Clinical Diagnostics의 회장 겸 CEO와 Cochlear의 CEO를 역임했습니다.
이번 임명은 PacBio가 임상 유전체학으로의 확장을 계속하는 동안 Smith의 진단 및 실험실 테스트 시장에 대한 전문성을 활용하는 것을 목표로 합니다. Smith의 임명과 동시에 2023년부터 이사회에 있었던 David Meline이 그의 직위에서 물러납니다.
PacBio의 회장 겸 CEO인 Christian Henry는 Smith의 임상 진단 및 유전체학에 대한 깊은 전문성과 고성장 기업을 확장한 경험이 PacBio가 임상 유전체학 시장에서 성장하는 데 귀중한 자산이 될 것이라고 강조했습니다.
PacBio (NASDAQ: PACB) a annoncé la nomination de Chris Smith à son Conseil d'Administration, avec effet immédiat. Smith, actuellement PDG de NeoGenomics (NASDAQ:NEO), apporte une vaste expérience dans les sciences de la vie et les industries de la santé. Auparavant, il a été Président et PDG d'Ortho Clinical Diagnostics et PDG de Cochlear.
Cette nomination vise à tirer parti de l'expertise de Smith dans les marchés des diagnostics et des tests de laboratoire alors que PacBio continue son expansion dans la génomique clinique. Concomitamment à la nomination de Smith, David Meline, qui a siégé au Conseil depuis 2023, démissionne de son poste.
Christian Henry, Président et PDG de PacBio, a souligné la profonde expertise de Smith dans le domaine des diagnostics cliniques et de la génomique, ainsi que son expérience dans la mise à l'échelle d'entreprises à forte croissance, comme des atouts précieux pour la future croissance de PacBio sur le marché de la génomique clinique.
PacBio (NASDAQ: PACB) hat die Ernennung von Chris Smith in seinen Vorstand bekannt gegeben, die sofort in Kraft tritt. Smith, der derzeit CEO von NeoGenomics (NASDAQ:NEO) ist, bringt umfangreiche Erfahrung in den Lebenswissenschaften und der Gesundheitsbranche mit. Zuvor war er Vorsitzender und CEO von Ortho Clinical Diagnostics und CEO von Cochlear.
Die Ernennung soll Smiths Fachwissen in den Bereichen Diagnostik und Labortests nutzen, während PacBio seine Expansion in die klinische Genomik fortsetzt. Zeitgleich mit Smiths Ernennung tritt David Meline, der seit 2023 im Vorstand ist, von seiner Position zurück.
Christian Henry, Präsident und CEO von PacBio, hob Smiths umfassende Expertise in klinischer Diagnostik und Genomik sowie seine Erfahrung im Wachstum von schnell wachsenden Unternehmen als wertvolle Vermögenswerte für PacBios zukünftiges Wachstum im Bereich klinische Genomik hervor.
- Addition of board member with extensive diagnostics and laboratory testing expertise
- Strategic alignment with company's expansion into clinical genomics market
- New director brings experience in scaling high-growth companies
- None.
PacBio to leverage Chris' extensive expertise in diagnostics and laboratory testing markets, as Board Member David Meline steps down.
MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of Chris Smith to its Board of Directors, effective today. Mr. Smith is currently the Chief Executive Officer of NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company.
Mr. Smith, a seasoned executive with extensive experience in the life sciences and healthcare industries, brings a strong track record of leadership in genomics, diagnostics, and corporate strategy. As CEO of NeoGenomics, a leading provider of oncology testing services, he has overseen the company’s continued growth and innovation in precision medicine.
"We are thrilled to welcome Chris to the PacBio Board,” said Christian Henry, President and Chief Executive Officer of PacBio. "Mr. Smith’s deep expertise in clinical diagnostics and genomics, combined with his leadership experience in scaling high-growth companies, will be invaluable as we seek to continue to expand into the clinical genomics market.”
Prior to NeoGenomics, Mr. Smith served as Chairman and CEO of Ortho Clinical Diagnostics which was sold to Quidel Corporation in December 2021. Prior to that, Mr. Smith was the CEO of Cochlear Limited and has served on several different boards of directors in both public and private companies. Mr. Smith holds a Bachelor of Science Degree in Journalism from Texas A&M University.
“I am honored to join PacBio’s Board at such an exciting time in the company’s journey,” said Chris Smith. “PacBio is at the forefront of innovation in sequencing technology, and I look forward to contributing to its mission of enabling the promise of genomics to improve human health.”
While Mr. Smith is joining the Board of PacBio, David Meline is resigning from the Board, effective today. Mr. Meline has served on the Board since 2023 and has played an important role in helping the Board drive the business and strategy of the Company.
“David has been a valued member of our Board, providing exceptional leadership and insight,” said Christian Henry, President and CEO, “On behalf of the entire company and Board, I want to express our appreciation for his contributions and wish him continued success in future endeavors.”
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our HiFi long-read sequencing and our SBB® short-read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
Forward Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the uses, coverage, advantages, and benefits or expected uses, advantages or benefits of using, PacBio products or technologies; continued expansion into the clinical genomics market; and other future events. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results, including potential performance, quality and regulatory issues; inability to expand into the clinical genomics market; and third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption "Risk Factors." These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.
Contacts
Investors and Media:
Todd Friedman
ir@pacificbiosciences.com
FAQ
Who is the new board member appointed to PacBio (PACB) in January 2024?
What is Chris Smith's background before joining PacBio's (PACB) board?
Why did PacBio (PACB) appoint Chris Smith to its board?
Who left PacBio's (PACB) board following Chris Smith's appointment?
